![]() Sequencing is performed on Illumina NextSeq500/550 instruments and the data are analyzed through custom bioinformatics pipelines. The DNA and RNA (cDNA) NGS library preparations are both based on custom QiaSeq chemistry (Qiagen) that includes unique molecular indices for the assessment of library complexity. The test is performed on DNA and RNA extracted from tumor-rich regions of formalin-fixed/paraffin-embedded tissue. The GeneTrails® Comprehensive Solid Tumor Panel has national coverage for qualifying Medicare and Medicare Advantage patients across all solid tumors. The DNA panel includes genes recently linked to immuno-therapy resistance (HLA, B2M, TAP, TAPBP, JAK1, IFNGR1, IFGR2). The partner-agnostic RNA gene fusion panel that is part of the CSTP encompasses all fusions for which FDA-approved therapies are available, as well as targets for ongoing clinical trials. In addition, it can be used to select therapies that have pan-cancer approval (pembrolizumab for MSI-high, larotrectinib and entrectinib for NTRK gene fusions). It covers genes that are informative for the use of FDA-approved therapies in non-small cell lung cancer (EGFR, BRAF, ALK, ROS1), colorectal cancer (KRAS, NRAS, BRAF), breast cancer (PIK3CA), and bladder cancer (FGFR2/3). CSTP is intended for the analysis of solid tumors from patients with clinically advanced disease (stage III or IV). The test can detect microsatellite instability and provides an estimate of tumor mutation burden (TMB). The GeneTrails ® Comprehensive Solid Tumor Panel (CSTP) is a next-generation sequencing (NGS) test comprised of two amplicon-based libraries (one DNA, one RNA/cDNA) used to screen for clinically informative gene alterations that are important in making therapeutic decisions, including SNVs, in/dels, copy number alterations and gene fusion events. GeneTrails® Solid Tumor Fusion Gene panel (RNA sequencing panel). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |